A World Without Pharmacy Benefit Companies… …Means Employers Would Have to Go it Alone Pharmacy benefit companies play an important and unique role in the drug supply and payment chain. While they are best known for lowering drug costs through
PBMs are committed to helping the patients we serve stay at home safely with reliable, convenient access to their needed prescription drugs. PBMs recognize that home delivery can provide an alternative way of safely accessing needed maintenance medications and
(Washington, D.C.) — As drugstore lobbyists descend on Albany today, it is important to highlight how pharmacy benefit managers (PBMs) advocate for consumers and health plan sponsors in the fight to keep prescription drugs accessible and affordable. It is equally
PBM Principles on Patient Access to Prescription Drugs During the COVID-19 Pandemic During this public health emergency, PBMs are committed to helping the patients we serve practice social distancing and stay at home safely with convenient, reliable access to their
(Washington, D.C.) — As the Energy and Commerce Subcommittee on Health examines ways to bring more transparency to prescription drug prices, the Pharmaceutical Care Management Association (PCMA) is confirming its principles on transparency in the prescription drug supply chain. PCMA
In case you missed it, Ike Brannon, senior fellow at the Jack Kemp Foundation and former senior economist for the United States Treasury and U.S. Congress, explains the problem with misguided policies targeting pharmacy benefit companies in a new RealClearMarkets
For millions of Americans, the prescription drug delivery system works: people, for the most part, can access the medications they need when they need them, and at the cost they expect and can afford. But “millions of Americans” does not
(Washington, D.C.) — As the House Committee on Oversight and Reform continues its investigation into drug manufacturers’ pricing strategies, the Pharmaceutical Care Management Association (PCMA) is releasing new data on the impact of blocking competition for top-selling medications. Brand-name drug manufacturers
While debating important legislative proposals that can impact patients’ health and access to medications, the discussion should rely on solid facts and evidence. Today, we’re highlighting new reputable third-party research and analyses by economists which underscore that legislation focused on
©2024 PCMA. All Rights Reserved.
